Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

NCT05420220 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
COMBINATION_PRODUCT: Axitinib

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd